Panbela Therapeutics

Panbela Therapeutics develops small-molecule therapies targeting sphingolipid signaling pathways in oncology. Its pipeline includes ivivimal, a synthetic sphingolipid analog tested in a Phase 2 trial for hepatocellular carcinoma (per ClinicalTrials.gov, 2023). The company's research emphasizes solid tumors, including pancreatic and colorectal cancers.

No institutional investors or strategic partners are publicly disclosed for Panbela Therapeutics. The company has not reported any venture capital backing, corporate partnerships, or licensing agreements in public filings or press releases.

Panbela focuses exclusively on synthetic sphingolipid analogs, a mechanism distinct from the dominant approaches in oncology (e.g., immune checkpoint inhibitors, targeted kinase inhibitors). This niche reduces direct competition but also caps pipeline breadth, as sphingolipid pathways remain less validated in clinical settings.

Panbela Therapeutics does not appear on major stock exchanges. Its ownership structure and registration status remain unclear from public records. The firm has not filed an S-1 or disclosed any public trading symbol.

The firm's most advanced asset, ivivimal, completed a Phase 2 trial for advanced hepatocellular carcinoma (ClinicalTrials.gov identifier unknown as of 2023). Other preclinical programs target pancreatic and colorectal cancers, but no Phase 1 or Phases 3 trial results have been made public.

Panbela Therapeutics lists its headquarters in Waconia, Minnesota, United States. No additional office locations have been disclosed.

No named executives, scientific advisors, or board members are listed in public filings or on the firm's website. The company has not issued press releases or regulatory filings that identify key personnel as of mid-2025.